Physician profile
Nathaniel Bump
NPI 1003449398
$556.86
in general payments reported to CMS, 2019-2025
14 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $266 · 2022: $84.63 · 2023: $78.80 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $143.95 | 2021 | |
| Smith+Nephew, INC. | $69.41 | 2023-2025 | Collagenase Santyl, Regranex |
| Abbvie INC. | $54.14 | 2021-2025 | |
| Convatec INC. | $54.08 | 2023 | |
| Amarin Pharma, INC. | $47.62 | 2021 | |
| Triad Life Sciences INC. | $34.39 | 2022 | |
| Genentech USA, INC. | $30.43 | 2022 | |
| Reprise Biomedical, INC. | $21.47 | 2025 | Miro 3d |
| Hartmann USA, INC. | $20.75 | 2025 | Zetuvit Plus 10x10 P10 |
| Kci USA, INC. | $19.81 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.38 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.58 | 2025 | Nuzyra |
| Lilly USA, LLC | $13.98 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Bump listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.